ivonescimab vs pd-l1/pd-l2/vista antagonist ca-170
| ivonescimab | pd-l1/pd-l2/vista antagonist ca-170 | |
|---|---|---|
| Developers | 9 | 1 |
| Clinical trials | 4 | 0 |
| FDA decisions | 2 | 0 |
| Generic name | Ivonescimab | PD-L1/PD-L2/VISTA Antagonist CA-170 |
Analyze any biotech with AI
Full pipeline, catalysts, financials & FDA data — with evidence-backed multi-agent analysis.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company